SPRR3 and diabetic cardiomyopathy: Moreover, 12 weeks of SPRC treatment, especially in the medium-dose group (40 mg·kg−1·day−1), alleviated almost all the morphological and functional phenotype of diabetic cardiomyopathy in db/db mice, which indicated the protective effect of SPRC on diabetic cardiomyopathy.